Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody shot could tackle stubborn acne Results expected Oct 2026 (estimated)
-
New drug aims to calm painful skin flares in hidradenitis suppurativa
Disease control Recruiting nowThis early-stage trial is testing a new drug called HB0043 in 15 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. The drug is a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) to reduc…
Phase 1/2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody drug HB0056 begins first human safety trial
Knowledge-focused Recruiting nowThis early-stage trial is testing the safety of a single dose of HB0056, a new bispecific antibody, in 46 healthy adults aged 18 to 55. Participants are randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves…
Phase 1 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:18 UTC